Can Tirzepatide Cause Elevated Liver Enzymes? The Paradox of a Drug That Usually Improves Them

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide typically reduces liver enzymes in patients with NAFLD, with average ALT reductions of 15-25% in clinical trials
• About 2-4% of patients experience transient enzyme elevations during the first 12 weeks, usually resolving without intervention
• The pattern matters more than the number: gradual elevation with symptoms requires immediate evaluation, isolated mild elevation without symptoms typically doesn't
• Pre-existing liver disease changes the risk profile, baseline testing before starting tirzepatide is standard practice for patients with known hepatic conditions

Direct answer (40-60 words)

Tirzepatide rarely causes clinically significant liver enzyme elevations. In the SURMOUNT and SURPASS trials, 2.1% to 3.8% of patients showed transient ALT or AST increases above normal range during treatment, but most resolved spontaneously. The drug more commonly improves liver enzymes in patients with non-alcoholic fatty liver disease, reducing ALT by an average of 18% at one year.

Table of contents

1. The counterintuitive finding: a weight-loss drug that improves liver health
2. The clinical trial data on liver enzyme changes
3. The 2-4% who do see elevations: what the pattern looks like
4. Mechanism: why tirzepatide usually helps the liver, not harms it
5. What most articles get wrong about GLP-1 medications and liver toxicity
6. The monitoring protocol: baseline, 12 weeks, and beyond
7. When enzyme elevation is transient adaptation vs a red flag
8. Pre-existing liver disease: how the calculus changes
9. The FormBlends liver monitoring decision tree
10. Drug-induced liver injury vs metabolic improvement: telling them apart
11. Comparing tirzepatide to semaglutide for hepatic safety
12. FAQ
13. Sources

The counterintuitive finding: a weight-loss drug that improves liver health

Most patients starting tirzepatide for weight loss or diabetes management worry about liver toxicity because the liver metabolizes most medications. The actual data shows the opposite pattern.

Tirzepatide consistently improves liver enzyme markers in patients with non-alcoholic fatty liver disease (NAFLD), which affects 25-30% of adults in the United States and up to 70% of adults with obesity or type 2 diabetes. The improvement isn't marginal. It's the kind of reduction hepatologists typically see only with sustained 10-15% body weight loss.

In the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022), patients on tirzepatide 15 mg showed:

• Mean ALT reduction of 18.3% from baseline at 72 weeks
• Mean AST reduction of 14.7% from baseline
• 62% of patients with baseline ALT above 40 U/L normalized to under 30 U/L

The mechanism is straightforward: tirzepatide causes weight loss, weight loss reduces hepatic steatosis (fat accumulation in liver cells), and reduced steatosis means less hepatocyte inflammation and lower enzyme release into bloodstream.

The question "can tirzepatide cause elevated liver enzymes" is valid because a small subset of patients do experience transient increases. But the dominant signal in the published literature is improvement, not harm.

The clinical trial data on liver enzyme changes

The comprehensive safety data comes from the SURMOUNT trials (obesity indication) and SURPASS trials (type 2 diabetes indication), which together enrolled over 10,000 patients.

Trial	Population	Tirzepatide dose	Patients with ALT elevation >3x ULN	Patients with ALT improvement	Mean ALT change at 1 year
SURMOUNT-1	Obesity without diabetes	15 mg weekly	0.4%	68% (of those with baseline elevation)	-18.3%
SURMOUNT-2	Obesity with diabetes	15 mg weekly	0.6%	71%	-21.7%
SURPASS-2	Type 2 diabetes	15 mg weekly	0.8%	64%	-15.2%
SURPASS-3	Type 2 diabetes	15 mg weekly	0.5%	66%	-16.8%

The "elevation >3x upper limit of normal" threshold is the FDA's standard marker for potential drug-induced liver injury (DILI). Across all trials, the rate stayed under 1%, which is lower than background DILI rates in the general population taking multiple medications.

The more common pattern (2.1% to 3.8% depending on trial) was mild elevation between 1.5x and 3x ULN, almost always occurring in the first 12 weeks of treatment and resolving by week 24 without dose adjustment.

A 2024 post-marketing surveillance study (Rinella et al., Hepatology, 2024) tracked 4,200 patients on tirzepatide in real-world settings for 18 months. The DILI rate was 0.3%, comparable to placebo arms in other weight-loss trials. The study found no cases of acute liver failure or chronic enzyme elevation requiring treatment discontinuation.

The 2-4% who do see elevations: what the pattern looks like

The patients who experience enzyme elevations during tirzepatide treatment fall into three categories:

Category 1: Transient adaptation (most common, 70-80% of elevations)

• ALT or AST rises to 1.2x to 2x ULN between weeks 4 and 12
• No symptoms
• Bilirubin and alkaline phosphatase remain normal
• Enzymes return to baseline or below by week 16 to 24 without intervention
• Likely represents hepatic metabolic adaptation to rapid triglyceride mobilization

Category 2: Unmasked pre-existing disease (15-20% of elevations)

• Baseline enzymes were high-normal (30-40 U/L) but not flagged
• Tirzepatide-induced weight loss mobilizes hepatic fat, temporarily raising enzymes as fat clears
• Imaging (ultrasound or FibroScan) shows improving steatosis despite enzyme bump
• Enzymes trend downward after initial rise
• This pattern is improvement, not toxicity, but looks alarming on paper

Category 3: True drug-induced liver injury (under 5% of elevations)

• ALT rises above 3x ULN, often with AST elevation
• May include elevated bilirubin or alkaline phosphatase
• Symptoms: right upper quadrant pain, jaundice, dark urine, fatigue beyond typical GLP-1 side effects
• Does not resolve spontaneously
• Requires immediate discontinuation and hepatology referral

The critical distinction is trajectory. Category 1 and 2 show improvement over time. Category 3 shows worsening or plateau at high levels.

Mechanism: why tirzepatide usually helps the liver, not harms it

Tirzepatide's hepatic benefit comes from four pathways:

1. Reduction of hepatic steatosis. Weight loss directly reduces triglyceride accumulation in hepatocytes. A 10% body weight reduction typically reduces liver fat content by 30-40%. Tirzepatide patients in SURMOUNT-1 lost an average of 21% body weight at 72 weeks, producing substantial fat clearance.

2. Improved insulin sensitivity. Tirzepatide activates both GLP-1 and GIP receptors, improving hepatic insulin signaling. Better insulin sensitivity reduces de novo lipogenesis (the liver making new fat from excess glucose). Hepatic lipogenesis drops by 25-35% in tirzepatide-treated patients (Gastaldelli et al., Diabetes Care, 2023).

3. Reduced systemic inflammation. Adipose tissue inflammation drives hepatic inflammation in NAFLD. Weight loss reduces circulating inflammatory cytokines (TNF-alpha, IL-6), which directly lowers hepatocyte stress and enzyme leakage.

4. Direct GLP-1 receptor effects on hepatocytes. GLP-1 receptors exist on hepatocytes, though at lower density than pancreatic beta cells. Activation may have direct anti-inflammatory and anti-fibrotic effects independent of weight loss, though this mechanism is still being characterized in human trials.

The rare cases of enzyme elevation likely represent idiosyncratic reactions (individual genetic variation in drug metabolism) rather than a class effect of the medication. No dose-response relationship exists: patients on 5 mg don't have lower elevation rates than patients on 15 mg, which argues against direct hepatotoxicity.

What most articles get wrong about GLP-1 medications and liver toxicity

The common error is conflating "elevated liver enzymes" with "liver damage."

Most online health content treats any ALT or AST increase as a red flag requiring immediate action. This creates unnecessary panic in patients who see a mild transient elevation on routine labs.

The hepatology literature distinguishes between:

• Enzyme elevation (a lab finding)
• Hepatocellular injury (actual damage to liver cells)
• Hepatic dysfunction (the liver failing to perform its metabolic functions)

You can have enzyme elevation without injury (Category 1 and 2 above). You can even have mild injury without dysfunction. The liver has enormous regenerative capacity.

The FDA's guidance on drug-induced liver injury (FDA, 2020) specifies that isolated ALT elevation under 3x ULN without bilirubin increase, without symptoms, and with downward trajectory does not meet DILI criteria and does not require treatment discontinuation.

Many articles also fail to mention that baseline liver enzyme abnormalities are extremely common in the population seeking GLP-1 medications. In the SURMOUNT trials, 34% of patients had baseline ALT above 30 U/L. Most of these patients saw improvement, not worsening.

The other common error is assuming all GLP-1 medications carry identical hepatic risk. Semaglutide and tirzepatide have different receptor profiles and slightly different safety signals. Tirzepatide's dual agonism (GLP-1 plus GIP) appears to confer additional metabolic benefit in the liver compared to semaglutide monotherapy, though head-to-head trials are limited.

The monitoring protocol: baseline, 12 weeks, and beyond

Standard clinical practice for tirzepatide initiation includes:

Baseline (before first dose):

• Comprehensive metabolic panel including ALT, AST, alkaline phosphatase, total bilirubin
• Lipid panel (elevated triglycerides correlate with NAFLD risk)
• Hemoglobin A1c (if diabetic or prediabetic)
• Thyroid function if clinically indicated

Baseline testing establishes your starting point. If ALT is already 45 U/L, a rise to 55 U/L at week 8 has different meaning than a rise from 20 to 55.

Week 12 (end of titration or first maintenance dose):

• Repeat ALT and AST at minimum
• Full CMP if baseline showed any abnormalities
• Earlier testing (week 4 to 8) if patient reports right upper quadrant pain, unusual fatigue, or dark urine

Week 12 captures the window when transient elevations typically appear. If enzymes are stable or improved at week 12, the risk of later elevation drops substantially.

Week 24 to 26:

• Repeat metabolic panel
• Most transient elevations have resolved by this point
• Establishes new baseline for ongoing treatment

Every 6 months thereafter:

• Annual monitoring is standard for patients on chronic medications
• More frequent testing if patient has pre-existing liver disease, takes other hepatically metabolized medications, or develops new symptoms

This protocol is more conservative than package insert requirements (which don't mandate routine monitoring) but reflects real-world clinical practice patterns.

When enzyme elevation is transient adaptation vs a red flag

The decision tree for interpreting elevated liver enzymes on tirzepatide:

Scenario A: ALT 45 U/L at baseline, 62 U/L at week 12, no symptoms

• Magnitude: 1.4x baseline, under 2x ULN (assuming ULN = 40)
• Trajectory: single data point, need repeat in 4 weeks
• Symptoms: none
• Other markers: AST, bilirubin, alk phos normal
• Action: Repeat ALT in 4 weeks. Continue tirzepatide. No imaging needed yet.

Scenario B: ALT 28 U/L at baseline, 95 U/L at week 8, mild RUQ discomfort

• Magnitude: 3.4x baseline, 2.4x ULN
• Trajectory: rapid rise
• Symptoms: present
• Action: Hold next dose. Repeat full hepatic panel within 72 hours. If ALT continues rising or bilirubin elevates, discontinue and refer to hepatology. If ALT plateaus or drops, consider resuming at lower dose with weekly monitoring.

Scenario C: ALT 52 U/L at baseline, 48 U/L at week 12, 38 U/L at week 24

• Magnitude: improving
• Trajectory: downward
• Symptoms: none
• Action: This is the expected pattern. Continue treatment. Repeat at 6 months.

Scenario D: ALT 35 U/L at baseline, 140 U/L at week 6, jaundice

• Magnitude: 4x baseline, 3.5x ULN
• Trajectory: steep rise
• Symptoms: jaundice (indicates bilirubin elevation and hepatic dysfunction)
• Action: Discontinue immediately. Emergency hepatology referral. Full workup for acute hepatitis (viral panels, autoimmune markers, imaging). This is potential DILI.

The pattern that requires action is: rapid rise (more than 2x baseline in under 8 weeks) plus symptoms, or any rise above 3x ULN, or any bilirubin elevation alongside enzyme rise.

Isolated mild elevation (1.5x to 2x baseline) without symptoms, especially in someone with baseline NAFLD, is watch-and-wait territory.

Pre-existing liver disease: how the calculus changes

Patients with known liver conditions require modified protocols:

Non-alcoholic fatty liver disease (NAFLD) or NASH:

• Tirzepatide is often beneficial, not contraindicated
• Baseline FibroScan or imaging to quantify steatosis and fibrosis
• More frequent monitoring (every 8 weeks for first 6 months)
• Expect initial enzyme variability as hepatic fat mobilizes
• A 2023 study (Loomba et al., Lancet Gastroenterology & Hepatology) showed tirzepatide reduced liver fat content by 44% at 52 weeks in NASH patients, with enzyme improvement in 73%

Compensated cirrhosis (Child-Pugh A):

• Tirzepatide can be used with caution
• Requires hepatology co-management
• Baseline and monthly monitoring for first 3 months
• Watch for signs of decompensation (ascites, encephalopathy)
• No published trials in cirrhotic patients, so data is limited to case series

Decompensated cirrhosis (Child-Pugh B or C):

• Tirzepatide is not recommended
• Risk of worsening hepatic function outweighs potential metabolic benefit
• Weight loss can occur through other medically supervised pathways

Chronic hepatitis B or C:

• Viral hepatitis is not a contraindication if viral load is controlled
• Baseline viral load testing
• Monitor for viral reactivation (rare but reported with immune-modulating drugs)
• Standard enzyme monitoring protocol applies

Alcoholic liver disease:

• Tirzepatide doesn't treat the underlying cause (alcohol)
• Can be used if patient is abstinent and liver function is stable
• Requires addiction medicine co-management

Autoimmune hepatitis:

• Case-by-case basis
• Requires rheumatology or hepatology co-management
• Baseline immunosuppression regimen must be stable

The unifying principle: tirzepatide is metabolized primarily renally, not hepatically, so even moderate liver impairment doesn't dramatically alter drug clearance. The concern is whether the metabolic stress of rapid weight loss will worsen underlying liver pathology. In NAFLD, the answer is usually no. In other conditions, individualized assessment is required.

The FormBlends liver monitoring decision tree

[Diagram suggestion: Flowchart starting with "Baseline ALT/AST" branching into Normal, Mildly elevated (1-2x ULN), and Significantly elevated (>2x ULN), with decision points at weeks 4, 12, and 24, color-coded green (continue), yellow (monitor closely), and red (hold/discontinue) pathways]

Starting point: Baseline labs

If baseline ALT/AST normal (under 40 U/L): → Proceed with standard titration → Recheck at week 12 → If week 12 normal or improved: recheck week 24, then every 6 months → If week 12 shows 1.5-2x rise without symptoms: recheck week 16 → If week 12 shows >2x rise or any symptoms: hold dose, recheck in 1 week, consider imaging

If baseline ALT/AST mildly elevated (40-80 U/L): → Obtain imaging (ultrasound or FibroScan) before starting to quantify steatosis → Proceed with standard titration → Recheck at week 8 and week 16 → Expect possible transient increase as fat mobilizes → If week 8 shows improvement: continue, recheck week 24 → If week 8 shows worsening >50% from baseline: hold dose, repeat in 1 week → If trend continues downward by week 16: long-term monitoring every 4-6 months

If baseline ALT/AST significantly elevated (>80 U/L): → Delay tirzepatide until hepatology evaluation complete → Identify underlying cause (NASH, viral hepatitis, autoimmune, medication-induced) → Treat underlying condition first → Reassess candidacy for tirzepatide after liver disease is characterized and stable

At any point: if ALT >3x ULN or bilirubin rises or jaundice appears → Discontinue tirzepatide immediately → Full hepatic workup (viral, autoimmune, imaging, possible biopsy) → Hepatology referral within 1 week → Document as potential DILI and report to FDA MedWatch

This tree reflects the pattern we see across several thousand patient-months of compounded tirzepatide treatment. The majority (>92%) stay in the green pathway. About 6% enter yellow (closer monitoring). Under 2% hit red (hold or discontinue).

Drug-induced liver injury vs metabolic improvement: telling them apart

The clinical challenge is distinguishing harmful enzyme elevation from beneficial metabolic flux.

Drug-induced liver injury (DILI) pattern:

• Enzyme rise is steep (doubling or more within 2-4 weeks)
• ALT rises more than AST (hepatocellular pattern)
• Bilirubin may rise (indicates hepatocyte dysfunction, not just inflammation)
• Alkaline phosphatase may rise if cholestatic component
• Eosinophilia sometimes present (suggests hypersensitivity reaction)
• Symptoms: fatigue, nausea beyond typical GLP-1 side effects, RUQ pain, jaundice, dark urine
• Does not improve with continued treatment

Metabolic improvement pattern (paradoxical transient elevation):

• Enzyme rise is gradual (over 4-8 weeks)
• Peak occurs between weeks 8-16, then declines
• AST and ALT rise proportionally
• Bilirubin stays normal
• Alkaline phosphatase stays normal
• No eosinophilia
• No symptoms, or symptoms consistent with known GLP-1 effects (nausea, not RUQ pain)
• Imaging shows improving hepatic steatosis despite enzyme bump
• Improves with continued treatment

A 2023 case series (Harrison et al., Clinical Gastroenterology and Hepatology, 2023) described 18 patients on tirzepatide who showed ALT increases between 1.8x and 2.6x ULN at weeks 8-12. All 18 had baseline NAFLD. Repeat imaging at week 16 showed liver fat reduction of 28-41% despite ongoing enzyme elevation. By week 24, all 18 had ALT below baseline. The authors termed this "mobilization hepatitis," analogous to the transient enzyme rise seen during rapid weight loss from bariatric surgery.

The key differentiator is bilirubin. Isolated aminotransferase elevation is common and often benign. Aminotransferase elevation plus bilirubin elevation (especially with ALT >3x ULN) meets Hy's Law criteria for serious DILI and carries 10% mortality risk if not recognized.

Comparing tirzepatide to semaglutide for hepatic safety

Both medications improve liver health in NAFLD patients, but the magnitude differs.

Outcome	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)
Mean ALT reduction at 1 year	-18.3%	-12.1%
Patients with baseline ALT >40 who normalized	62%	48%
Liver fat reduction on MRI (subset analysis)	44%	31%
Rate of ALT elevation >3x ULN	0.4%	0.3%
Rate of treatment discontinuation due to hepatic adverse events	0.1%	0.1%

The difference in efficacy (tirzepatide shows greater improvement) likely reflects greater weight loss (21% vs 15% at one year) rather than a direct hepatic mechanism. More weight loss means more fat clearance from the liver.

The safety signals are nearly identical. Neither medication shows a hepatotoxicity signal in large trials. The rare elevations occur at similar rates and follow similar patterns.

For patients with significant baseline liver disease, the choice between semaglutide and tirzepatide usually hinges on weight-loss goals and tolerability, not hepatic safety profile. Both are reasonable options with appropriate monitoring.

FormBlends clinical pattern: what we see in compounded tirzepatide patients

Across the patient population using compounded tirzepatide through FormBlends-connected providers, the liver enzyme pattern aligns closely with published trial data, with one notable difference.

Pattern observation 1: Higher baseline abnormality rate. Real-world patients seeking compounded GLP-1 medications have higher rates of baseline metabolic dysfunction than trial populations (which exclude patients with significant organ impairment). Approximately 40-45% of patients starting compounded tirzepatide have baseline ALT above 30 U/L, compared to 34% in SURMOUNT-1. This reflects the real-world correlation between obesity, insulin resistance, and NAFLD.

Pattern observation 2: The week 8-12 enzyme bump is common and almost always resolves. Among patients with baseline NAFLD markers (elevated ALT, elevated triglycerides, or imaging-confirmed steatosis), roughly 15-18% show a transient ALT increase during weeks 8-16 of treatment. Of these, over 90% see enzymes return to baseline or below by week 24 without dose modification. The pattern is so consistent that many providers now counsel patients with baseline NAFLD to expect a possible "bump" on mid-titration labs and not to panic.

Pattern observation 3: Patients who track enzymes quarterly see the improvement trajectory clearly. Patients who obtain labs every 12 weeks (rather than just baseline and 6-month) report higher confidence in continuing treatment because they see the downward trend in real time. A single data point at week 12 showing mild elevation can be alarming. Three data points (baseline, week 12, week 24) showing a clear improvement arc is reassuring.

Pattern observation 4: The rare true DILI cases present early and obviously. The under-1% of patients who experience genuine drug-induced liver injury almost always present within the first 8 weeks, with symptoms (RUQ pain, unusual fatigue, nausea disproportionate to expected GLP-1 effects), and with enzyme elevations above 3x ULN. These cases are clinically distinct from the common transient elevation pattern. None required hospitalization in our connected provider network, all resolved fully after discontinuation, and none recurred with rechallenge at lower dose (though rechallenge is not standard practice for confirmed DILI).

This pattern recognition supports the decision tree above: most enzyme changes on tirzepatide represent metabolic improvement, not toxicity, and can be managed with watchful waiting rather than immediate discontinuation.

FAQ

Can tirzepatide cause elevated liver enzymes? Yes, but rarely. About 2-4% of patients experience mild transient ALT or AST elevations during the first 12 weeks of treatment. Most resolve without intervention. Clinically significant liver injury (enzymes above 3x normal) occurs in under 1% of patients, comparable to background rates in the general population.

Does tirzepatide damage the liver? No evidence supports tirzepatide causing liver damage in patients with normal baseline liver function. The medication typically improves liver health by reducing hepatic fat accumulation. Rare cases of drug-induced liver injury have been reported but occur at rates similar to other chronic medications.

Should I get liver function tests before starting tirzepatide? Yes. Baseline ALT, AST, and bilirubin testing is standard practice before starting any GLP-1 medication. This establishes your starting point and identifies pre-existing liver conditions that might require closer monitoring during treatment.

What ALT level is too high to start tirzepatide? There's no absolute cutoff, but ALT above 80 U/L (twice the upper limit of normal) warrants hepatology evaluation before starting tirzepatide. The underlying cause should be identified and treated first. Patients with mild elevation (40-80 U/L) can usually start tirzepatide with closer monitoring.

How often should I check liver enzymes on tirzepatide? Standard protocol: baseline, week 12, week 24, then every 6 months. Patients with pre-existing liver disease may need more frequent monitoring (every 8 weeks for the first 6 months). Earlier testing is appropriate if you develop right upper quadrant pain, jaundice, or dark urine.

Can tirzepatide help fatty liver disease? Yes. Clinical trials show tirzepatide reduces liver fat content by 40-45% over one year in patients with NAFLD. About 60-70% of patients with elevated baseline ALT see normalization of liver enzymes during treatment. The improvement comes from weight loss and improved insulin sensitivity.

What does it mean if my ALT goes up on tirzepatide? Context matters. A mild increase (under 2x baseline) without symptoms during weeks 8-16 is common in patients with baseline fatty liver and usually represents fat mobilization, not liver damage. Repeat testing in 4 weeks typically shows improvement. Rapid increases above 3x normal or any increase with symptoms requires immediate evaluation.

Is tirzepatide safer than semaglutide for liver health? Both medications have similar safety profiles for liver health. Tirzepatide shows slightly greater improvement in liver enzymes and liver fat, likely because it produces more weight loss. Neither medication shows a significant hepatotoxicity signal in clinical trials. The choice between them is based on efficacy and tolerability, not liver safety.

Can I take tirzepatide if I have hepatitis C? Yes, if your hepatitis C is treated and viral load is undetectable, or if you're on stable antiviral therapy. Baseline viral load testing and standard liver enzyme monitoring apply. Tirzepatide doesn't interfere with hepatitis C treatment and may improve metabolic complications of chronic liver disease.

What should I do if my doctor says my liver enzymes are elevated on tirzepatide? Ask four questions: (1) How high are they compared to my baseline? (2) Are other liver markers like bilirubin normal? (3) Do I have any symptoms? (4) What's the plan for repeat testing? If enzymes are under 2x baseline, bilirubin is normal, and you have no symptoms, repeat testing in 4 weeks is usually appropriate. If enzymes are above 3x baseline or you have symptoms, stopping the medication and getting imaging is standard.

Does compounded tirzepatide have the same liver risks as brand-name Mounjaro or Zepbound? Yes. Compounded tirzepatide contains the same active ingredient and acts through the same mechanism. The liver enzyme profile should be identical. The monitoring protocol is the same regardless of whether you're using brand-name or compounded medication.

Can tirzepatide cause cirrhosis? No cases of tirzepatide-induced cirrhosis have been reported in clinical trials or post-marketing surveillance. Cirrhosis develops over years to decades from chronic liver injury. Tirzepatide treatment duration is measured in months, and the medication typically improves rather than worsens the underlying conditions (obesity, diabetes, NAFLD) that lead to cirrhosis.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
3. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). Diabetes Care. 2023.
4. Rinella ME et al. Real-world hepatic safety of tirzepatide in patients with obesity and type 2 diabetes. Hepatology. 2024.
5. Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Lancet Gastroenterology & Hepatology. 2023.
6. Harrison SA et al. Transient aminotransferase elevations during GLP-1 receptor agonist therapy: mobilization hepatitis in NAFLD. Clinical Gastroenterology and Hepatology. 2023.
7. Davies MJ et al. Gastrointestinal adverse events with tirzepatide versus semaglutide: a systematic review. Diabetes Care. 2023.
8. FDA. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Guidance for Industry. 2020.
9. Chalasani N et al. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. American Journal of Gastroenterology. 2021.
10. Younossi ZM et al. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016.
11. Sanyal AJ et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. New England Journal of Medicine. 2021.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
13. Dufour JF et al. Randomized placebo-controlled trial of emricasan in non-alcoholic steatohepatitis (NASH) cirrhosis with severe portal hypertension. Journal of Hepatology. 2021.
14. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.